Margin. The result is seen as pivotal for the future ties of the nation with the European Union. And u. S. Banks are braced for the worth order since the quarter for the worse quarter since the financial crisis. Jp morgan kicks off a big rank week. Good morning, it is 6 00 a. M. In london. It is getting hot here. With an untamed virus irrationalional exuberance in stocks. It could get tricky. Goldman has upped their view of their earnings. Yall so have the gilead story in terms of remdesivir helping the severely ill despite the untamed virus in florida exceeding the peaks of new york and texas. They are still below consensus and there are deals there. The dollar drops. Two straight weeks of a demolition of the dollar. Yields traded at. 63. Do you buy the rally . Im a believer, are you . Copper is the shining narrative. Copper is ripping it up there this morning. You are looking at the longest 20 16. Streak since is that a wakeup call to the Treasury Department . On willudis turn the sa
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 33,040,000 shares, a drop of 6.1% from the April 30th total of 35,170,000 shares. Based on an average daily trading volume, of 5,610,000 shares, […]
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 7,500 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $6.72, for a total transaction of $50,400.00. Following the sale, the chief executive officer now owns 1,270,273 shares in the company, valued […]
Ardelyx, Inc (NASDAQ:ARDX) CEO Sells $50,400 00 in Stock wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Piper Sandler reissued their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday morning, Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock. ARDX has been the topic of a number of other research reports. SVB Leerink began coverage on shares of […]